Details der Publikation - Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis

Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:68
Enthalten in:	Digestive diseases and sciences - 68(2023), 5 vom: 17. März, Seite 1709-1713

Sprache:	Englisch

Beteiligte Personen:	Dalal, Rahul S. [VerfasserIn] Goksel, Behiye [VerfasserIn] Hamilton, Matthew J. [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.87$jGastroenterologie
Themen:	Eosinophils Gastritis Infliximab Infusion Ulcerative colitis Vedolizumab

Anmerkungen:	© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

doi:	10.1007/s10620-023-07866-9

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2134703466

Internformat


LEADER	01000naa a22002652 4500
001	OLC2134703466
003	DE-627
005	20230510163203.0
007	cr uuu---uuuuu
008	230510s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10620-023-07866-9 \|2 doi
035			\|a (DE-627)OLC2134703466
035			\|a (DE-He213)s10620-023-07866-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.87$jGastroenterologie \|2 bkl
100	1		\|a Dalal, Rahul S. \|e verfasserin \|4 aut
245	1	0	\|a Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023
650		4	\|a Eosinophils
650		4	\|a Gastritis
650		4	\|a Infliximab
650		4	\|a Vedolizumab
650		4	\|a Ulcerative colitis
650		4	\|a Infusion
700	1		\|a Goksel, Behiye \|4 aut
700	1		\|a Hamilton, Matthew J. \|4 aut
773	0	8	\|i Enthalten in \|t Digestive diseases and sciences \|d Springer US, 1934 \|g 68(2023), 5 vom: 17. März, Seite 1709-1713 \|h Online-Ressource \|w (DE-627)320525384 \|w (DE-600)2015102-0 \|w (DE-576)099426617 \|x 1573-2568 \|7 nnns
773	1	8	\|g volume:68 \|g year:2023 \|g number:5 \|g day:17 \|g month:03 \|g pages:1709-1713
856	4	0	\|u https://dx.doi.org/10.1007/s10620-023-07866-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.87$jGastroenterologie \|q VZ \|0 106409999 \|0 (DE-625)106409999
951			\|a AR
952			\|d 68 \|j 2023 \|e 5 \|b 17 \|c 03 \|h 1709-1713

Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände